Name | Number of supported studies | Average coverage | |
---|---|---|---|
lung | 16 studies | 37% ± 17% | |
peripheral blood | 16 studies | 34% ± 11% | |
kidney | 8 studies | 29% ± 7% | |
intestine | 8 studies | 34% ± 15% | |
lymph node | 5 studies | 31% ± 13% | |
liver | 5 studies | 25% ± 12% | |
pancreas | 4 studies | 58% ± 14% | |
placenta | 4 studies | 30% ± 9% | |
eye | 4 studies | 29% ± 11% | |
uterus | 4 studies | 38% ± 15% | |
breast | 4 studies | 28% ± 5% | |
brain | 4 studies | 26% ± 5% | |
bone marrow | 3 studies | 29% ± 9% | |
adrenal gland | 3 studies | 26% ± 6% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
adrenal gland | 100% | 4520.02 | 258 / 258 | 100% | 48.06 | 230 / 230 |
bladder | 100% | 3275.52 | 21 / 21 | 100% | 61.52 | 504 / 504 |
esophagus | 100% | 3028.21 | 1445 / 1445 | 100% | 59.39 | 183 / 183 |
kidney | 100% | 3107.58 | 89 / 89 | 100% | 47.31 | 901 / 901 |
liver | 100% | 1791.48 | 226 / 226 | 100% | 34.76 | 406 / 406 |
lung | 100% | 2615.38 | 578 / 578 | 100% | 68.07 | 1155 / 1155 |
ovary | 100% | 3073.63 | 180 / 180 | 100% | 64.35 | 430 / 430 |
pancreas | 100% | 1871.00 | 328 / 328 | 100% | 53.97 | 178 / 178 |
skin | 100% | 3399.97 | 1809 / 1809 | 100% | 49.01 | 472 / 472 |
stomach | 100% | 2284.11 | 359 / 359 | 100% | 46.43 | 286 / 286 |
thymus | 100% | 2464.47 | 653 / 653 | 100% | 53.63 | 605 / 605 |
uterus | 100% | 2780.78 | 170 / 170 | 100% | 75.46 | 459 / 459 |
brain | 100% | 2254.19 | 2637 / 2642 | 100% | 41.05 | 705 / 705 |
intestine | 100% | 3577.93 | 966 / 966 | 100% | 47.70 | 526 / 527 |
prostate | 100% | 3374.20 | 245 / 245 | 100% | 57.06 | 501 / 502 |
breast | 100% | 2853.14 | 459 / 459 | 100% | 59.13 | 1115 / 1118 |
adipose | 100% | 2779.46 | 1204 / 1204 | 0% | 0 | 0 / 0 |
blood vessel | 100% | 3660.02 | 1335 / 1335 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 100% | 27.68 | 80 / 80 |
lymph node | 0% | 0 | 0 / 0 | 100% | 47.73 | 29 / 29 |
muscle | 100% | 3580.44 | 803 / 803 | 0% | 0 | 0 / 0 |
spleen | 100% | 2486.80 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 68.96 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 44.27 | 1 / 1 |
heart | 99% | 2438.87 | 854 / 861 | 0% | 0 | 0 / 0 |
peripheral blood | 93% | 1651.00 | 868 / 929 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0016567 | Biological process | protein ubiquitination |
GO_0006511 | Biological process | ubiquitin-dependent protein catabolic process |
GO_0045116 | Biological process | protein neddylation |
GO_0051775 | Biological process | response to redox state |
GO_0043687 | Biological process | post-translational protein modification |
GO_0031466 | Cellular component | Cul5-RING ubiquitin ligase complex |
GO_0005654 | Cellular component | nucleoplasm |
GO_0005829 | Cellular component | cytosol |
GO_0005737 | Cellular component | cytoplasm |
GO_0005634 | Cellular component | nucleus |
GO_0061630 | Molecular function | ubiquitin protein ligase activity |
GO_0019788 | Molecular function | NEDD8 transferase activity |
GO_0005507 | Molecular function | copper ion binding |
GO_0061663 | Molecular function | NEDD8 ligase activity |
GO_0005515 | Molecular function | protein binding |
GO_0008270 | Molecular function | zinc ion binding |
GO_0097602 | Molecular function | cullin family protein binding |
Gene name | RNF7 |
Protein name | Ring finger protein 7 RING-box protein 2 (Rbx2) (CKII beta-binding protein 1) (CKBBP1) (RING finger protein 7) (Regulator of cullins 2) (Sensitive to apoptosis gene protein) |
Synonyms | RBX2 SAG ROC2 |
Description | FUNCTION: Probable component of the SCF (SKP1-CUL1-F-box protein) E3 ubiquitin ligase complex which mediates the ubiquitination and subsequent proteasomal degradation of target proteins involved in cell cycle progression, signal transduction and transcription . CRLs complexes and ARIH1 collaborate in tandem to mediate ubiquitination of target proteins, ARIH1 mediating addition of the first ubiquitin on CRLs targets (By similarity). Through the RING-type zinc finger, seems to recruit the E2 ubiquitination enzyme to the complex and brings it into close proximity to the substrate. Promotes the neddylation of CUL5 via its interaction with UBE2F. May play a role in protecting cells from apoptosis induced by redox agents. . |
Accessions | Q9UBF6 F8WEU8 ENST00000393000.3 [Q9UBF6-3] ENST00000477012.5 [Q9UBF6-2] ENST00000477393.1 ENST00000273480.4 [Q9UBF6-1] ENST00000480908.1 [Q9UBF6-4] |